By combining quantum chemistry and computing power, QuantumBio Inc. says it can model large macromolecules far better and more efficiently than currently available mechanics-based software. The company's tools promise better predictability of chemical and physical properties for virtual screening, QSAR, ADME/Tox, lead optimization and docking.
200 Innovation Park
Suite 224
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The companies announced the publication of Phase III data that they said provide rationale for moving forward in a confirmatory trial.
The Swiss neuroscience specialist has extended its cash runway into late 2027, but will still need positive readouts in the coming months, including for its wholly owned Parkinson’s candidate.
Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.
The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.
Recent moves in the industry include C-suite changes at Mitsubishi Tanabe Pharma and Oculis Holding, plus clock.bio gets a new chief business officer from BioNTech.
Approval in alpha- and beta-thalassemia by a Sept. 7 action date seemed assured, but an FDA review of proposed REMS regarding potential liver injury pushed it back to Dec. 7.
Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.
